Magnesium in midlife: why it matters more than we think

We tend to look to hormones, thyroid function or iron levels when energy dips, sleep worsens or stress tolerance shifts in midlife. But one mineral is often overlooked.

Magnesium sits behind hundreds of processes in the body. Most of it is stored in bone, skeletal muscle and soft tissue, where it supports energy production, nerve signalling and metabolic function. It’s needed for ATP to work in its active form, for insulin signalling, thyroid hormone conversion and the regulation of vascular tone.

Demand for magnesium tends to increase with age. By midlife, cumulative stress, reduced metabolic flexibility, medication use, and changes in gut function can all increase requirements, while also increasing losses (Pickering et al., 2020; Barbagallo et al., 2010; Hess et al., 2012; Ford et al., 2020).

When magnesium status is suboptimal, the signs are often subtle at first. Fatigue. Lighter or more fragmented sleep. Muscle tightness. Palpitations. A reduced tolerance to stress. Slower metabolic response.

In practice, these symptoms are usually investigated in primary care through thyroid markers, iron status or inflammatory indicators. Serum magnesium may also be included, but this reflects only what is circulating in the blood at that moment. Less than one per cent of total body magnesium is found in the bloodstream (Costello et al., 2016), and intracellular status is not routinely assessed within the NHS, despite being more reflective of functional availability.

A serum result within range does not necessarily reflect what is happening at tissue level, and intracellular insufficiency can be present while laboratory values appear normal. In this context, magnesium status may be overlooked. Symptoms are then attributed to stress, hormonal transition, perimenopause or ageing itself (Newson, 2022), while a key underlying cofactor remains unexamined.

Intracellular magnesium and system function

Magnesium’s role becomes clearer when you look at what is happening inside the cell.

Inside the cell, it binds to ATP to form Mg-ATP – the form required for effective energy transfer (Elin, 2010). Energy can still be produced when magnesium is low, but the process is less efficient, so recovery tends to take longer, and physical output can be harder to sustain.

Magnesium also helps regulate the balance between excitatory and calming signals in the brain. It influences NMDA receptor activity and supports inhibitory GABA signalling. When intracellular levels fall, excitatory signalling tends to dominate, which can present as lighter sleep, a “wired but tired” feeling and reduced stress tolerance (Wang et al., 2018).

It also plays a role in vascular function. Magnesium is required for smooth muscle relaxation, including within blood vessels (Whelton et al., 2018). 

Magnesium in the midlife terrain

By the fourth and fifth decades, several systems in the body begin adjusting at the same time. Hormone patterns change, metabolic flexibility narrows and sensitivity to accumulated stress increases. Magnesium supports many of these processes, and when levels are marginal, it may not be recognised. This is often when things start to feel different. Energy becomes less stable, recovery takes longer, and stress is harder to tolerate. Symptoms rarely sit within one system and often present across several.

Blood sugar regulation is often one of the first areas affected. Even mild insulin resistance increases urinary magnesium losses (Barbagallo et al., 2010), yet magnesium is also required for effective insulin signalling (Hruby & Meigs, 2015). Demand rises while retention becomes less efficient, which can present as energy dips, cravings or reduced satiety.

Thyroid function is linked to magnesium. It is required for the conversion of T4 to T3 (Mooren et al., 2011), which determines how thyroid hormone is used at tissue level. Lower availability can coincide with reduced metabolic drive, even when thyroid markers appear within range.

Magnesium also participates in progesterone production and oestrogen metabolism (Seelig, 1990). Lower levels may sit alongside heavier cycles, breast tenderness, menstrual migraines or disrupted sleep, even when hormone levels appear within expected ranges.

Around half of the total body magnesium is stored in bone, with a substantial proportion in skeletal muscle. Both tissues are metabolically active and constantly remodelling. As lean mass increases, magnesium needs tend to rise with it, so women using resistance training to maintain muscle in midlife may require more.

Gastrointestinal and nervous system changes are also common. Magnesium supports smooth muscle relaxation and gut-brain signalling. Lower availability can affect motility, contributing to bloating, tension or bowel irregularity.

The magnesium deficiency blind spot

Magnesium demand rises with stress, poor sleep, training, illness and medication use. At the same time, modern diets often provide less than expected. Soil depletion, food processing and lower intake of mineral-rich foods all contribute (Thomas, 2007). Absorption can also be affected by digestive function and ongoing stress.

When intake is low or losses increase, the body draws on intracellular and skeletal stores to maintain circulating levels (Nielsen, 2018). Magnesium is essential for cardiac rhythm and neuromuscular stability, so serum levels are tightly regulated and kept within a narrow range.

Routine NHS testing relies almost entirely on serum magnesium. This reflects what is circulating in the blood at a single point in time, not what is available within muscle, the heart or the nervous system. A result within range confirms circulating levels are being maintained. It does not reflect tissue availability.

Serum values can therefore appear normal while intracellular stores are already being depleted. This creates a blind spot. People may present with fatigue, muscle tension, palpitations, migraines, reduced stress tolerance or early metabolic changes. Blood tests come back normal, yet symptoms persist.

Red blood cell (RBC) magnesium provides a closer indication of intracellular status. It is not routinely available in primary care, but can be accessed privately in the UK and gives a better sense of longer-term tissue availability.

Testing, however, is not always essential. In many cases, the clinical picture already points to increased demand. Magnesium repletion is often a reasonable starting point.

Restoring intracellular magnesium

Leafy greens, nuts, seeds, legumes, mineral-rich water and well-sourced animal foods all contribute magnesium. Once intracellular stores are depleted, diet alone is not always enough to restore them.

In those situations, supplementation is often required.

Magnesium supplements are not interchangeable. The mineral is always bound to another compound, which affects absorption and function. What matters is the amount of elemental magnesium – the fraction available for use, not the total weight listed on the label.

Different forms serve different purposes. Magnesium oxide contains a high proportion of elemental magnesium but is poorly absorbed and acts mainly within the gastrointestinal tract. It may help with constipation, but it is not usually selected when the aim is to restore intracellular status (Firoz & Graber, 2001).

Other forms are more reliably absorbed and better tolerated (Walker et al., 2003). Magnesium glycinate is often used where sleep, stress or neuromuscular tension are present. Magnesium citrate can support bowel motility. Magnesium malate is sometimes used where fatigue is a feature. Forms such as taurate or threonate are used in more specific contexts, although the evidence base varies.

Guidance typically suggests total daily magnesium intakes of around 350-400 mg from diet and supplements combined (Institute of Medicine, 1997; EFSA, 2015).

Topical approaches, including magnesium sprays and Epsom salt baths, are also widely used. Evidence for systemic absorption is mixed, but they are often used for muscular relaxation and can sit alongside oral intake (Gröber et al., 2015).

In summary

Magnesium does not always present as a clear deficiency. It often sits in the background of symptoms that don’t fully resolve.

In midlife, when several systems are adjusting at once, that becomes more relevant. Energy, sleep, metabolic function and stress tolerance all rely on it, yet it is rarely explored beyond a basic blood test.

If symptoms are ongoing, it is often worth looking beyond a single test result. Working with a registered nutrition professional can help explore this in more detail and guide a more individual approach.

References

Baker, S. et al. (2013). Audit of serum magnesium levels in acute medical admissions. BMJ Quality Improvement Reports, 2(1). https://doi.org/10.1136/bmjquality.u201111.w1113

Barbagallo, M. and Dominguez, L.J. (2008). Magnesium and aging. Current Pharmaceutical Design, 16(7), 832–839. PubMed ID: 18288948

Barbagallo, M., Dominguez, L.J., Galioto, A., Ferlisi, A., Cani, C., Malfa, L., Pineo, A. and Busardo, A. (2010). Role of magnesium in insulin action, diabetes and cardio-metabolic syndrome. Current Opinion in Clinical Nutrition & Metabolic Care, 13(4), 525–530. https://doi.org/10.1097/MCO.0b013e328339f9b1

Cinar, V. et al. (2011). Magnesium supplementation and testosterone levels in athletes and sedentary subjects. Biological Trace Element Research, 140(1), 18–23.

Costello, R.B. et al. (2016). Perspective: Is serum magnesium concentration an adequate measure of magnesium status in humans? Advances in Nutrition, 7(6), 977–983. https://doi.org/10.3945/an.116.012419

EFSA Panel on Dietetic Products, Nutrition and Allergies (2015). Scientific opinion on dietary reference values for magnesium. EFSA Journal, 13(7), 4186. https://doi.org/10.2903/j.efsa.2015.4186

Elin, R.J. (2010). Magnesium: the fifth but forgotten electrolyte. American Journal of Clinical Pathology, 133(5), 664–672. https://doi.org/10.1309/AJCPM1YPIUQTRRG2

Firoz, M., & Graber, M. (2001). Bioavailability of US commercial magnesium preparations. Magnesium Research, 14(4), 257–262.

Ford, A.C. et al. (2020). Proton pump inhibitors: possible adverse effects. BMJ, 369, m1533. https://doi.org/10.1136/bmj.m1533

Gröber, U., Schmidt, J., & Kisters, K. (2015). Magnesium in prevention and therapy. Nutrients, 7(9), 8199–8226. https://doi.org/10.3390/nu7095388

Hess, M.W. et al. (2012). Hypomagnesemia caused by proton pump inhibitors – current evidence and practical implications. Alimentary Pharmacology & Therapeutics, 36(5), 405–413. https://doi.org/10.1111/j.1365-2036.2012.05201.x

Hruby, A. and Meigs, J.B. (2015). Magnesium and glucose metabolism. Current Opinion in Lipidology, 26(1), 10–20. https://doi.org/10.1097/MOL.0000000000000134

Institute of Medicine (1997). Dietary reference intakes for calcium, phosphorus, magnesium, vitamin D, and fluoride. National Academy Press. https://doi.org/10.17226/5776

Maggio, M. et al. (2006). Magnesium, IGF-1, and testosterone in older men. Magnesium Research, 19(3), 192–198.

Makrides, M., Crosby, D.D., Bain, E., & Crowther, C.A. (2014). Magnesium supplementation in pregnancy. Cochrane Database of Systematic Reviews, (4), CD000937. https://doi.org/10.1002/14651858.CD000937.pub2

Miyazaki, T., Karube, M., Matsuzaki, T., et al. (2003). Vitamin B6 and magnesium metabolism interactions. Magnesium Research, 16(2), 119–126.

Mooren, F.C. et al. (2011). Oral magnesium supplementation reduces insulin resistance in non-diabetic subjects: a double-blind, placebo-controlled, randomised trial. Diabetes, Obesity and Metabolism, 13(3), 281–284. https://doi.org/10.1111/j.1463-1326.2010.01332.x

Newson, L. (2022). Menopause: All You Need to Know in One Concise Manual. London: Penguin Life.

Nielsen, F.H. (2018). Assessment of magnesium status. Nutrition Reviews, 76(9), 749–763. https://doi.org/10.1093/nutrit/nuy020

Pickering, G. et al. (2020). Magnesium status and stress: the vicious circle concept revisited. Nutrients, 12(11), 3672. https://doi.org/10.3390/nu12113672

Rosanoff, A., Weaver, C.M., & Rude, R.K. (2012). Suboptimal magnesium status in the United States: are the health consequences underestimated? Nutrition Reviews, 70(3), 153–164. https://doi.org/10.1111/j.1753-4887.2011.00465.x

Rosanoff, A., Plesset, M. and Weaver, C.M. (2016). Suboptimal magnesium status in the United States: are the health consequences underestimated? Nutrition Reviews, 74(9), 579–598. https://doi.org/10.1093/nutrit/nuw023

Seelig, M.S. (1990). Consequences of magnesium deficiency on the enhancement of stress reactions; preventive and therapeutic implications. Journal of the American College of Nutrition, 9(5), 452–459. https://doi.org/10.1080/07315724.1990.10720304

Slutsky, I., Abumaria, N., Wu, L.J., et al. (2010). Enhancement of learning and memory by elevating brain magnesium. Neuron, 65(2), 165–177. https://doi.org/10.1016/j.neuron.2009.12.026

Sontia, B., Touyz, R.M., et al. (2008). Magnesium transport and cardiovascular implications of taurine–magnesium interactions. Hypertension Research, 31(6), 1173–1181.

Thomas, D. (2007). The mineral depletion of foods available to us as a nation (1940–2002). Nutrition and Health, 19(1–2), 21–55. https://doi.org/10.1177/026010600701900205

Uwitonze, A.M., & Razzaque, M.S. (2018). Role of magnesium in vitamin D activation and function. The Journal of the American Osteopathic Association, 118(3), 181–189. https://doi.org/10.7556/jaoa.2018.037

Walker, A.F., Marakis, G., Christie, S., & Byng, M. (2003). Mg citrate found more bioavailable than other Mg preparations in a randomised, double-blind study. Magnesium Research, 16(3), 183–191.

Wang, J. et al. (2018). Magnesium supplementation improves anxiety and stress responses: a review. Nutritional Neuroscience, 21(5), 321–331. https://doi.org/10.1080/1028415X.2017.1305480

Whelton, P.K. et al. (2018). Effects of magnesium supplementation on blood pressure: a meta-analysis. Hypertension, 71(4), 631–639. https://doi.org/10.1161/HYPERTENSIONAHA.117.10748

Zhao, B. et al. (2016). Correlation of serum ferritin and magnesium with cognitive function in women with iron deficiency. Biological Trace Element Research, 174(2), 371–376. https://doi.org/10.1007/s12011-016-0716-y